Dow Up0.11% Nasdaq Down0.56%

Dicerna Pharmaceuticals, Inc. (DRNA)

-NasdaqGS
13.09 Down 0.55(4.03%) 12:53PM EDT - Nasdaq Real Time Price
ProfileGet Profile for:
Dicerna Pharmaceuticals, Inc.
Building 1
Suite 120
Watertown, MA 02472
United States - Map
Phone: 617-621-8097
Website: http://www.dicerna.com

Details 
Index Membership:N/A
Sector:Healthcare
Industry:Biotechnology
Full Time Employees:22

Business Summary 

Dicerna Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the discovery and development of treatments for liver diseases and cancers based on a proprietary RNA interference technology platform in the United States and internationally. The company’s development programs include DCR-PH1 for the treatment of primary hyperoxaluria 1 (PH1) through targeting the liver metabolic enzyme glycolate oxidase; and other rare inherited diseases involving disease target genes expressed in the liver, including hemophilia, porphyria, hypercholesterolemia, hemoglobinopathies, alpha-1-antitrypsin deficiency hepatocyte, inclusions, and others. It is also developing DCR-M1711 for the treatment of various cancers through targeting the MYC oncogene, a gene that causes or promotes cancer when abnormally expressed or activated, as well as a product candidate targeting the oncogene KRAS; and a second product candidate targeting an oncogene. The company has a research collaboration and license agreement with Kyowa Hakko Kirin Co., Ltd. for the research, development, and commercialization of drug delivery platforms and DsiRNA molecules for therapeutic targets, primarily in oncology; and a license agreement with City of Hope, an academic research and medical center, to manufacture, use, offer for sale, sell, and import products related to DsiRNA for the prevention and treatment of various diseases in humans. Dicerna Pharmaceuticals, Inc. was founded in 2006 and is headquartered in Watertown, Massachusetts.

Key Statistics


Company Websites 
Home Page
Search Yahoo! for:
More on Dicerna Pharmaceuticals, Inc.

Key Executives 
 PayExercised
Dr. Douglas M. Fambrough III, Ph.D., 45
Co-Founder, Chief Exec. Officer, Pres and Director
547.00K0.00
Mr. James E. Dentzer , 47
Chief Financial Officer and Principal Accounting Officer
74.00K0.00
Dr. Bob D. Brown Ph.D., 49
Chief Scientific Officer and Sr. VP
511.00K0.00
Mr. James B. Weissman , 51
Chief Bus. Officer
417.00K0.00
Dr. Mark Behlke M.D., Ph.D.,
Co-Founder and Member of Scientific Advisory Board
N/AN/A
Amounts are as of Dec 31, 2013 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc.Exercised is the value of options exercised during the fiscal year.
Currency in USD.
View Insiders